BioCardia, Inc. is a regenerative medicine company focused on developing new treatments for cardiovascular and pulmonary conditions using cellular and cell-derived therapies. Its lead candidate, the CardiAMP Cell Therapy System, is designed to treat heart failure and chronic myocardial ischemia. In addition, BioCardia is developing allogeneic cells therapeutic platform and offers the Helix biotherapeutic delivery system and Morph deflectable guides and sheaths.